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In a recent letter to the editor, Wetzels1 criticized our
randomized controlled trial on tacrolimus in patients with
membranous nephropathy (MGN).2 We strongly disagree
with his interpretation of our data for the following reasons:
1. We believe that our results clearly demonstrate that
tacrolimus represents a very potent therapeutic possibility
for MGN patients with nephrotic syndrome (NS) and
preserved renal function. The probability of remission
reached 94% after 18 months of therapy, tolerance was
very good and confirming that the achievement of NS
remission, even partial, renders the development of renal
insufficiency very unlikely,3 the risk of renal function
worsening was significantly higher among control patients.
NS relapsed in almost half of the patients after tacrolimus
withdrawal, but it is important to mention that no relapses
were detected in the period of tacrolimus withdrawal in
spite of very low drug doses.
2. Our results are very similar to those of Cattran
et al.4 using cyclosporin: a very high percentage of rapid
remissions but relapse of NS in approximately half of the
patients after drug withdrawal. After our trial, tacrolimus
was reintroduced in most of those patients with a relapse
of NS, entering in remission again (to be reported in future
publications). We believe that our data and those of
Cattran using cyclosporin outline two possible ways to
exploit the powerful effect of anticalcineurinics in MGN
(not merely due to hemodynamic effects, as recent studies
point to a direct influence of anticalcineurinics on the
structure and function of podocytes): a long-term treat-
ment with the lowest effective doses or investigation about
sequential immunosuppressive therapies that could avoid
the relapse of NS after anticalcineurinic withdrawal
(we are currently investigating this possibility with very
promising results).
3. Wetzels emphasized some nonsignificant imbalances
in our study (more patients 450 years in the control
group), whereas he obviates that 66% of treated patients of
450 years reached remission of NS in comparison with 0%
in the non-treated control group. There were no differ-
ences in baseline proteinuria and the reasons why some
patients did not reach 30 months of follow-up were loss of
follow-up or retirement of the patients because of renal
function worsening, as stated in the Methods section. The
important strengths of our study were the systematic use
of ACEI and ARB and the interval between diagnosis and
the onset of the study. We believe that our results are
particularly applicable to the important subset of MGN
that maintain NS for a long period of time without
spontaneous remissions.
4. We agree that alkylating agents have proven effective
in MGN. However, there is a general agreement about their
serious side effects and the need for less dangerous
therapeutic alternatives. In fact, Wetzels and co-workers5
shares our proposition about the restrictive use of
immunosuppressive agents for those patients with a more
aggressive presentation.6 In addition, preliminary pro-
spective studies favor anticalcineurinic drugs in compar-
ison with alkylating agents.7
5. The number of prospective trials such as ours on
MGN is very limited and they are absolutely necessary in a
disease with such a rate of spontaneous remission. Our
policy includes a conservative approach (with ACEI/ARB
in every case) for all the patients, waiting for the
appearance of a spontaneous remission. If NS persists for
more than 9–18 months (duration of this observation
period depends on patient’s characteristics), we recom-
mend a course of anticalcineurinics. But in those cases
with aggressive presentations (massive proteinuria accom-
panied by a rapid worsening of renal function), we still
prefer a course of steroids plus an alkylating agent.6 We
believe that clinicians need an open-minded vision to treat
a disease with such a variable presentation and course as
MGN, making the most of all the therapeutic alternatives
that have demonstrated a beneficial effect.
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